FY2025 Earnings Forecast for MRKR Issued By HC Wainwright

Marker Therapeutics, Inc. (NASDAQ:MRKR) – Research analysts at HC Wainwright issued their FY2025 earnings estimates for shares of Marker Therapeutics in a research note issued on Monday, December 8th. HC Wainwright analyst P. Trucchio forecasts that the company will post earnings per share of ($0.95) for the year. HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Marker Therapeutics’ current full-year earnings is ($0.65) per share. HC Wainwright also issued estimates for Marker Therapeutics’ Q4 2025 earnings at ($0.20) EPS, Q1 2026 earnings at ($0.22) EPS, Q2 2026 earnings at ($0.27) EPS, Q3 2026 earnings at ($0.27) EPS, Q4 2026 earnings at ($0.21) EPS, FY2026 earnings at ($0.97) EPS, FY2027 earnings at ($0.69) EPS, FY2028 earnings at ($0.62) EPS and FY2029 earnings at ($0.54) EPS.

Marker Therapeutics (NASDAQ:MRKR) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.69) by $0.57. Marker Therapeutics had a negative return on equity of 92.35% and a negative net margin of 304.56%.The business had revenue of $1.23 million for the quarter, compared to analyst estimates of $0.72 million.

MRKR has been the subject of several other reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Marker Therapeutics in a research note on Wednesday, October 8th. Zacks Research upgraded Marker Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, November 18th. Wall Street Zen cut Marker Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, November 30th. Finally, UBS Group reissued a “buy” rating on shares of Marker Therapeutics in a research note on Monday. Three investment analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Marker Therapeutics presently has an average rating of “Buy” and a consensus target price of $10.17.

Marker Therapeutics Stock Down 2.7%

NASDAQ:MRKR opened at $1.45 on Wednesday. The firm has a market capitalization of $24.17 million, a P/E ratio of -1.18 and a beta of 1.35. The company has a fifty day moving average of $1.07 and a 200 day moving average of $1.22. Marker Therapeutics has a 52 week low of $0.81 and a 52 week high of $5.95.

Hedge Funds Weigh In On Marker Therapeutics

Large investors have recently modified their holdings of the stock. Jane Street Group LLC purchased a new position in shares of Marker Therapeutics in the 2nd quarter worth $33,000. Virtu Financial LLC purchased a new position in shares of Marker Therapeutics in the third quarter valued at about $25,000. Finally, Two Sigma Investments LP purchased a new position in shares of Marker Therapeutics during the third quarter valued at about $33,000. Hedge funds and other institutional investors own 22.39% of the company’s stock.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.